IMRT 2018
SABR in stage I histologically proven NSCLC: an Italian multicenter observational study
OVERALL SURVIVAL
2B
1,0
DOM FROM LOCAL RECURRENCE REEDOM FROM NODAL RECURR NCE
FREEDOM FROM NODAL RECURRENCE
6.7 ear: 91.9
% 2 years: 90.9
% 3 years: 89.7
% 1 year: 91.9
% 2 years: 89.0
% 3 years: 85.5
% 2 years: 89.0
% 3 years: 85.5
0,8
0,6
DOM FROM DISTANT RECURRENCE DISEASE FREE SURVIVAL
DISEASE FREE SURVIVAL
0.4 ear: 82.9
% 2 years: 80.4
% 3 years: 75.9
% 1 year: 82.9
% 2 years: 70.2
% 3 years: 65.5
% 2 years: 70.2
% 3 years: 65.5
0,4
CANCER SPECIFIC SURVIVAL OVERALL SURVIVAL
OVERALL SURVIVAL
0,2
7.2
% 2 years: 88.9
% 3 years: 82.1
% 1 year: 94.0
% 2 years: 81.6
% 3 years: 68.0
ear: 94.0
% 2 years: 81.6
% 3 years: 68.0
0,0
96,00
,00
12,00
24,00
36,00
48,00
60,00
72,00
84,00
96,00
Time since enrollement (months)
Number at risk
196 165 107 63 37 15 7 4 1
1
Ricardi et al, Lung Cancer 2014
Made with FlippingBook - professional solution for displaying marketing and sales documents online